Global Alpha- Antitrypsin Deficiency Treatment Market Research Report 2024(Status and Outlook)
Report Overview:
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The Global Alpha- Antitrypsin Deficiency Treatment Market Size was estimated at USD 2057.50 million in 2023 and is projected to reach USD 3450.63 million by 2029, exhibiting a CAGR of 9.00% during the forecast period.
This report provides a deep insight into the global Alpha- Antitrypsin Deficiency Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Alpha- Antitrypsin Deficiency Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Alpha- Antitrypsin Deficiency Treatment market in any manner.
Global Alpha- Antitrypsin Deficiency Treatment Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Market Segmentation (by Type)
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Market Segmentation (by Application)
Clinic
Hospital
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Alpha- Antitrypsin Deficiency Treatment Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
The Global Alpha- Antitrypsin Deficiency Treatment Market Size was estimated at USD 2057.50 million in 2023 and is projected to reach USD 3450.63 million by 2029, exhibiting a CAGR of 9.00% during the forecast period.
This report provides a deep insight into the global Alpha- Antitrypsin Deficiency Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Alpha- Antitrypsin Deficiency Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Alpha- Antitrypsin Deficiency Treatment market in any manner.
Global Alpha- Antitrypsin Deficiency Treatment Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Market Segmentation (by Type)
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Market Segmentation (by Application)
Clinic
Hospital
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Alpha- Antitrypsin Deficiency Treatment Market
- Overview of the regional outlook of the Alpha- Antitrypsin Deficiency Treatment Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Alpha- Antitrypsin Deficiency Treatment Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Alpha- Antitrypsin Deficiency Treatment
1.2 Key Market Segments
1.2.1 Alpha- Antitrypsin Deficiency Treatment Segment by Type
1.2.2 Alpha- Antitrypsin Deficiency Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET COMPETITIVE LANDSCAPE
3.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Manufacturers (2019-2024)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Manufacturers (2019-2024)
3.3 Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Alpha- Antitrypsin Deficiency Treatment Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites, Area Served, Product Type
3.6 Alpha- Antitrypsin Deficiency Treatment Market Competitive Situation and Trends
3.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate
3.6.2 Global 5 and 10 Largest Alpha- Antitrypsin Deficiency Treatment Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT INDUSTRY CHAIN ANALYSIS
4.1 Alpha- Antitrypsin Deficiency Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2019-2024)
6.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)
6.4 Global Alpha- Antitrypsin Deficiency Treatment Price by Type (2019-2024)
7 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Alpha- Antitrypsin Deficiency Treatment Market Sales by Application (2019-2024)
7.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Application (2019-2024)
7.4 Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
8 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY REGION
8.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region
8.2 North America
8.2.1 North America Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Adverum Biotechnologies, Inc.
9.1.1 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.1.2 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.1.4 Adverum Biotechnologies, Inc. Business Overview
9.1.5 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.1.6 Adverum Biotechnologies, Inc. Recent Developments
9.2 Alnylam Pharmaceuticals, Inc.
9.2.1 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.2.2 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.2.4 Alnylam Pharmaceuticals, Inc. Business Overview
9.2.5 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.2.6 Alnylam Pharmaceuticals, Inc. Recent Developments
9.3 Applied Genetic Technologies Corporation
9.3.1 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
9.3.2 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
9.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.3.5 Applied Genetic Technologies Corporation Business Overview
9.3.6 Applied Genetic Technologies Corporation Recent Developments
9.4 Arrowhead Pharmaceuticals, Inc.
9.4.1 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.4.2 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.4.4 Arrowhead Pharmaceuticals, Inc. Business Overview
9.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
9.5 Carolus Therapeutics, Inc.
9.5.1 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.5.2 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.5.4 Carolus Therapeutics, Inc. Business Overview
9.5.5 Carolus Therapeutics, Inc. Recent Developments
9.6 Cevec Pharmaceuticals GmbH
9.6.1 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information
9.6.2 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview
9.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.6.4 Cevec Pharmaceuticals GmbH Business Overview
9.6.5 Cevec Pharmaceuticals GmbH Recent Developments
9.7 Dicerna Pharmaceuticals, Inc.
9.7.1 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.7.2 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.7.4 Dicerna Pharmaceuticals, Inc. Business Overview
9.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
9.8 Digna Biotech, S.L.
9.8.1 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.8.2 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.8.4 Digna Biotech, S.L. Business Overview
9.8.5 Digna Biotech, S.L. Recent Developments
9.9 Editas Medicine, Inc.
9.9.1 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.9.2 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.9.4 Editas Medicine, Inc. Business Overview
9.9.5 Editas Medicine, Inc. Recent Developments
9.10 Grifols, S.A.
9.10.1 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.10.2 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.10.4 Grifols, S.A. Business Overview
9.10.5 Grifols, S.A. Recent Developments
9.11 Inhibrx
9.11.1 Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information
9.11.2 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview
9.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.11.4 Inhibrx Business Overview
9.11.5 Inhibrx Recent Developments
9.12 Intellia Therapeutics, Inc.
9.12.1 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.12.2 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.12.4 Intellia Therapeutics, Inc. Business Overview
9.12.5 Intellia Therapeutics, Inc. Recent Developments
9.13 International Stem Cell Corporation
9.13.1 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
9.13.2 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
9.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.13.4 International Stem Cell Corporation Business Overview
9.13.5 International Stem Cell Corporation Recent Developments
9.14 Ionis Pharmaceuticals, Inc.
9.14.1 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.14.2 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.14.4 Ionis Pharmaceuticals, Inc. Business Overview
9.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
9.15 Kamada Ltd.
9.15.1 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.15.2 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.15.4 Kamada Ltd. Business Overview
9.15.5 Kamada Ltd. Recent Developments
9.16 Polyphor Ltd.
9.16.1 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.16.2 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.16.4 Polyphor Ltd. Business Overview
9.16.5 Polyphor Ltd. Recent Developments
9.17 ProMetic Life Sciences Inc.
9.17.1 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.17.2 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.17.4 ProMetic Life Sciences Inc. Business Overview
9.17.5 ProMetic Life Sciences Inc. Recent Developments
9.18 rEVO Biologics, Inc.
9.18.1 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.18.2 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.18.4 rEVO Biologics, Inc. Business Overview
9.18.5 rEVO Biologics, Inc. Recent Developments
9.19 Sangamo BioSciences, Inc.
9.19.1 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.19.2 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.19.4 Sangamo BioSciences, Inc. Business Overview
9.19.5 Sangamo BioSciences, Inc. Recent Developments
10 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET FORECAST BY REGION
10.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast
10.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country
10.2.3 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region
10.2.4 South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Alpha- Antitrypsin Deficiency Treatment by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2030)
11.1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2030)
11.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Application (2025-2030)
11.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application
11.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Alpha- Antitrypsin Deficiency Treatment
1.2 Key Market Segments
1.2.1 Alpha- Antitrypsin Deficiency Treatment Segment by Type
1.2.2 Alpha- Antitrypsin Deficiency Treatment Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET COMPETITIVE LANDSCAPE
3.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Manufacturers (2019-2024)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Manufacturers (2019-2024)
3.3 Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Alpha- Antitrypsin Deficiency Treatment Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites, Area Served, Product Type
3.6 Alpha- Antitrypsin Deficiency Treatment Market Competitive Situation and Trends
3.6.1 Alpha- Antitrypsin Deficiency Treatment Market Concentration Rate
3.6.2 Global 5 and 10 Largest Alpha- Antitrypsin Deficiency Treatment Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT INDUSTRY CHAIN ANALYSIS
4.1 Alpha- Antitrypsin Deficiency Treatment Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2019-2024)
6.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size Market Share by Type (2019-2024)
6.4 Global Alpha- Antitrypsin Deficiency Treatment Price by Type (2019-2024)
7 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Alpha- Antitrypsin Deficiency Treatment Market Sales by Application (2019-2024)
7.3 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Application (2019-2024)
7.4 Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
8 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION BY REGION
8.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.1.1 Global Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.1.2 Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region
8.2 North America
8.2.1 North America Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Alpha- Antitrypsin Deficiency Treatment Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Adverum Biotechnologies, Inc.
9.1.1 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.1.2 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.1.4 Adverum Biotechnologies, Inc. Business Overview
9.1.5 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.1.6 Adverum Biotechnologies, Inc. Recent Developments
9.2 Alnylam Pharmaceuticals, Inc.
9.2.1 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.2.2 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.2.4 Alnylam Pharmaceuticals, Inc. Business Overview
9.2.5 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.2.6 Alnylam Pharmaceuticals, Inc. Recent Developments
9.3 Applied Genetic Technologies Corporation
9.3.1 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
9.3.2 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
9.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
9.3.5 Applied Genetic Technologies Corporation Business Overview
9.3.6 Applied Genetic Technologies Corporation Recent Developments
9.4 Arrowhead Pharmaceuticals, Inc.
9.4.1 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.4.2 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.4.4 Arrowhead Pharmaceuticals, Inc. Business Overview
9.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments
9.5 Carolus Therapeutics, Inc.
9.5.1 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.5.2 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.5.4 Carolus Therapeutics, Inc. Business Overview
9.5.5 Carolus Therapeutics, Inc. Recent Developments
9.6 Cevec Pharmaceuticals GmbH
9.6.1 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information
9.6.2 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview
9.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.6.4 Cevec Pharmaceuticals GmbH Business Overview
9.6.5 Cevec Pharmaceuticals GmbH Recent Developments
9.7 Dicerna Pharmaceuticals, Inc.
9.7.1 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.7.2 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.7.4 Dicerna Pharmaceuticals, Inc. Business Overview
9.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments
9.8 Digna Biotech, S.L.
9.8.1 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.8.2 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.8.4 Digna Biotech, S.L. Business Overview
9.8.5 Digna Biotech, S.L. Recent Developments
9.9 Editas Medicine, Inc.
9.9.1 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.9.2 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.9.4 Editas Medicine, Inc. Business Overview
9.9.5 Editas Medicine, Inc. Recent Developments
9.10 Grifols, S.A.
9.10.1 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.10.2 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.10.4 Grifols, S.A. Business Overview
9.10.5 Grifols, S.A. Recent Developments
9.11 Inhibrx
9.11.1 Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information
9.11.2 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview
9.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.11.4 Inhibrx Business Overview
9.11.5 Inhibrx Recent Developments
9.12 Intellia Therapeutics, Inc.
9.12.1 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.12.2 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.12.4 Intellia Therapeutics, Inc. Business Overview
9.12.5 Intellia Therapeutics, Inc. Recent Developments
9.13 International Stem Cell Corporation
9.13.1 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
9.13.2 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
9.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.13.4 International Stem Cell Corporation Business Overview
9.13.5 International Stem Cell Corporation Recent Developments
9.14 Ionis Pharmaceuticals, Inc.
9.14.1 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.14.2 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.14.4 Ionis Pharmaceuticals, Inc. Business Overview
9.14.5 Ionis Pharmaceuticals, Inc. Recent Developments
9.15 Kamada Ltd.
9.15.1 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.15.2 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.15.4 Kamada Ltd. Business Overview
9.15.5 Kamada Ltd. Recent Developments
9.16 Polyphor Ltd.
9.16.1 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.16.2 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.16.4 Polyphor Ltd. Business Overview
9.16.5 Polyphor Ltd. Recent Developments
9.17 ProMetic Life Sciences Inc.
9.17.1 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.17.2 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.17.4 ProMetic Life Sciences Inc. Business Overview
9.17.5 ProMetic Life Sciences Inc. Recent Developments
9.18 rEVO Biologics, Inc.
9.18.1 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.18.2 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.18.4 rEVO Biologics, Inc. Business Overview
9.18.5 rEVO Biologics, Inc. Recent Developments
9.19 Sangamo BioSciences, Inc.
9.19.1 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
9.19.2 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
9.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Market Performance
9.19.4 Sangamo BioSciences, Inc. Business Overview
9.19.5 Sangamo BioSciences, Inc. Recent Developments
10 ALPHA- ANTITRYPSIN DEFICIENCY TREATMENT MARKET FORECAST BY REGION
10.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast
10.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country
10.2.3 Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region
10.2.4 South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Alpha- Antitrypsin Deficiency Treatment by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2030)
11.1.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Alpha- Antitrypsin Deficiency Treatment by Type (2025-2030)
11.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Application (2025-2030)
11.2.1 Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application
11.2.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Alpha- Antitrypsin Deficiency Treatment Market Size Comparison by Region (M USD)
Table 5. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2022)
Table 10. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites and Area Served
Table 12. Manufacturers Alpha- Antitrypsin Deficiency Treatment Product Type
Table 13. Global Alpha- Antitrypsin Deficiency Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Alpha- Antitrypsin Deficiency Treatment
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Alpha- Antitrypsin Deficiency Treatment Market Challenges
Table 22. Global Alpha- Antitrypsin Deficiency Treatment Sales by Type (K Units)
Table 23. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (M USD)
Table 24. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Type (2019-2024)
Table 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2019-2024)
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Type (2019-2024)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2019-2024)
Table 28. Global Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) by Type (2019-2024)
Table 29. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Application
Table 30. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application
Table 31. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (K Units)
Table 32. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2019-2024)
Table 33. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (M USD)
Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)
Table 35. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
Table 36. Global Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 37. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)
Table 38. North America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 39. Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 41. South America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 43. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 44. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 45. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Adverum Biotechnologies, Inc. Business Overview
Table 47. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 48. Adverum Biotechnologies, Inc. Recent Developments
Table 49. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 50. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 51. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Alnylam Pharmaceuticals, Inc. Business Overview
Table 53. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 54. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 55. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 56. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 57. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 59. Applied Genetic Technologies Corporation Business Overview
Table 60. Applied Genetic Technologies Corporation Recent Developments
Table 61. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 62. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 63. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Arrowhead Pharmaceuticals, Inc. Business Overview
Table 65. Arrowhead Pharmaceuticals, Inc. Recent Developments
Table 66. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 67. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 68. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Carolus Therapeutics, Inc. Business Overview
Table 70. Carolus Therapeutics, Inc. Recent Developments
Table 71. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 72. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 73. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Cevec Pharmaceuticals GmbH Business Overview
Table 75. Cevec Pharmaceuticals GmbH Recent Developments
Table 76. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 77. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 78. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Dicerna Pharmaceuticals, Inc. Business Overview
Table 80. Dicerna Pharmaceuticals, Inc. Recent Developments
Table 81. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 82. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 83. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Digna Biotech, S.L. Business Overview
Table 85. Digna Biotech, S.L. Recent Developments
Table 86. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 87. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 88. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Editas Medicine, Inc. Business Overview
Table 90. Editas Medicine, Inc. Recent Developments
Table 91. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 92. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 93. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Grifols, S.A. Business Overview
Table 95. Grifols, S.A. Recent Developments
Table 96. Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 97. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 98. Inhibrx Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Inhibrx Business Overview
Table 100. Inhibrx Recent Developments
Table 101. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 102. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 103. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Intellia Therapeutics, Inc. Business Overview
Table 105. Intellia Therapeutics, Inc. Recent Developments
Table 106. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 107. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 108. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. International Stem Cell Corporation Business Overview
Table 110. International Stem Cell Corporation Recent Developments
Table 111. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 112. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 113. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Ionis Pharmaceuticals, Inc. Business Overview
Table 115. Ionis Pharmaceuticals, Inc. Recent Developments
Table 116. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 117. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 118. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Kamada Ltd. Business Overview
Table 120. Kamada Ltd. Recent Developments
Table 121. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 122. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 123. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Polyphor Ltd. Business Overview
Table 125. Polyphor Ltd. Recent Developments
Table 126. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 127. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 128. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. ProMetic Life Sciences Inc. Business Overview
Table 130. ProMetic Life Sciences Inc. Recent Developments
Table 131. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 132. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 133. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. rEVO Biologics, Inc. Business Overview
Table 135. rEVO Biologics, Inc. Recent Developments
Table 136. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 137. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 138. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Sangamo BioSciences, Inc. Business Overview
Table 140. Sangamo BioSciences, Inc. Recent Developments
Table 141. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2030) & (K Units)
Table 142. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 144. North America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 146. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2030) & (K Units)
Table 148. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 150. South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Type (2025-2030) & (K Units)
Table 154. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Alpha- Antitrypsin Deficiency Treatment Price Forecast by Type (2025-2030) & (USD/Unit)
Table 156. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application (2025-2030)
Table 157. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Alpha- Antitrypsin Deficiency Treatment Market Size Comparison by Region (M USD)
Table 5. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Alpha- Antitrypsin Deficiency Treatment Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2022)
Table 10. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Alpha- Antitrypsin Deficiency Treatment Sales Sites and Area Served
Table 12. Manufacturers Alpha- Antitrypsin Deficiency Treatment Product Type
Table 13. Global Alpha- Antitrypsin Deficiency Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Alpha- Antitrypsin Deficiency Treatment
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Alpha- Antitrypsin Deficiency Treatment Market Challenges
Table 22. Global Alpha- Antitrypsin Deficiency Treatment Sales by Type (K Units)
Table 23. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (M USD)
Table 24. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Type (2019-2024)
Table 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2019-2024)
Table 26. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) by Type (2019-2024)
Table 27. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2019-2024)
Table 28. Global Alpha- Antitrypsin Deficiency Treatment Price (USD/Unit) by Type (2019-2024)
Table 29. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) by Application
Table 30. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application
Table 31. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (K Units)
Table 32. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2019-2024)
Table 33. Global Alpha- Antitrypsin Deficiency Treatment Sales by Application (2019-2024) & (M USD)
Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)
Table 35. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
Table 36. Global Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 37. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)
Table 38. North America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 39. Europe Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 41. South America Alpha- Antitrypsin Deficiency Treatment Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales by Region (2019-2024) & (K Units)
Table 43. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 44. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 45. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Adverum Biotechnologies, Inc. Business Overview
Table 47. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 48. Adverum Biotechnologies, Inc. Recent Developments
Table 49. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 50. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 51. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Alnylam Pharmaceuticals, Inc. Business Overview
Table 53. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 54. Alnylam Pharmaceuticals, Inc. Recent Developments
Table 55. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 56. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 57. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment SWOT Analysis
Table 59. Applied Genetic Technologies Corporation Business Overview
Table 60. Applied Genetic Technologies Corporation Recent Developments
Table 61. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 62. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 63. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Arrowhead Pharmaceuticals, Inc. Business Overview
Table 65. Arrowhead Pharmaceuticals, Inc. Recent Developments
Table 66. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 67. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 68. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Carolus Therapeutics, Inc. Business Overview
Table 70. Carolus Therapeutics, Inc. Recent Developments
Table 71. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 72. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 73. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Cevec Pharmaceuticals GmbH Business Overview
Table 75. Cevec Pharmaceuticals GmbH Recent Developments
Table 76. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 77. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 78. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Dicerna Pharmaceuticals, Inc. Business Overview
Table 80. Dicerna Pharmaceuticals, Inc. Recent Developments
Table 81. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 82. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 83. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Digna Biotech, S.L. Business Overview
Table 85. Digna Biotech, S.L. Recent Developments
Table 86. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 87. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 88. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Editas Medicine, Inc. Business Overview
Table 90. Editas Medicine, Inc. Recent Developments
Table 91. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 92. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 93. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Grifols, S.A. Business Overview
Table 95. Grifols, S.A. Recent Developments
Table 96. Inhibrx Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 97. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 98. Inhibrx Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Inhibrx Business Overview
Table 100. Inhibrx Recent Developments
Table 101. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 102. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 103. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Intellia Therapeutics, Inc. Business Overview
Table 105. Intellia Therapeutics, Inc. Recent Developments
Table 106. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 107. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 108. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. International Stem Cell Corporation Business Overview
Table 110. International Stem Cell Corporation Recent Developments
Table 111. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 112. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 113. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Ionis Pharmaceuticals, Inc. Business Overview
Table 115. Ionis Pharmaceuticals, Inc. Recent Developments
Table 116. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 117. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 118. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Kamada Ltd. Business Overview
Table 120. Kamada Ltd. Recent Developments
Table 121. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 122. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 123. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Polyphor Ltd. Business Overview
Table 125. Polyphor Ltd. Recent Developments
Table 126. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 127. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 128. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. ProMetic Life Sciences Inc. Business Overview
Table 130. ProMetic Life Sciences Inc. Recent Developments
Table 131. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 132. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 133. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. rEVO Biologics, Inc. Business Overview
Table 135. rEVO Biologics, Inc. Recent Developments
Table 136. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Basic Information
Table 137. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product Overview
Table 138. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Sangamo BioSciences, Inc. Business Overview
Table 140. Sangamo BioSciences, Inc. Recent Developments
Table 141. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2030) & (K Units)
Table 142. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 143. North America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 144. North America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 145. Europe Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 146. Europe Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 147. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Region (2025-2030) & (K Units)
Table 148. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Region (2025-2030) & (M USD)
Table 149. South America Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Country (2025-2030) & (K Units)
Table 150. South America Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 151. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Consumption Forecast by Country (2025-2030) & (Units)
Table 152. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Country (2025-2030) & (M USD)
Table 153. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Type (2025-2030) & (K Units)
Table 154. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Type (2025-2030) & (M USD)
Table 155. Global Alpha- Antitrypsin Deficiency Treatment Price Forecast by Type (2025-2030) & (USD/Unit)
Table 156. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) Forecast by Application (2025-2030)
Table 157. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Alpha- Antitrypsin Deficiency Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD), 2019-2030
Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) (2019-2030)
Figure 6. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Alpha- Antitrypsin Deficiency Treatment Market Size by Country (M USD)
Figure 11. Alpha- Antitrypsin Deficiency Treatment Sales Share by Manufacturers in 2023
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers in 2023
Figure 13. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type
Figure 18. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)
Figure 19. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023
Figure 20. Market Size Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)
Figure 21. Market Size Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application
Figure 24. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2019-2024)
Figure 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application in 2023
Figure 26. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)
Figure 27. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application in 2023
Figure 28. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
Figure 29. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)
Figure 30. North America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 32. U.S. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Alpha- Antitrypsin Deficiency Treatment Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 37. Germany Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023
Figure 44. China Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 50. South America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 51. Brazil Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Type (2025-2030)
Figure 65. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Application (2025-2030)
Figure 66. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Alpha- Antitrypsin Deficiency Treatment
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD), 2019-2030
Figure 5. Global Alpha- Antitrypsin Deficiency Treatment Market Size (M USD) (2019-2030)
Figure 6. Global Alpha- Antitrypsin Deficiency Treatment Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Alpha- Antitrypsin Deficiency Treatment Market Size by Country (M USD)
Figure 11. Alpha- Antitrypsin Deficiency Treatment Sales Share by Manufacturers in 2023
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Manufacturers in 2023
Figure 13. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Alpha- Antitrypsin Deficiency Treatment Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type
Figure 18. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)
Figure 19. Sales Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023
Figure 20. Market Size Share of Alpha- Antitrypsin Deficiency Treatment by Type (2019-2024)
Figure 21. Market Size Market Share of Alpha- Antitrypsin Deficiency Treatment by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application
Figure 24. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2019-2024)
Figure 25. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application in 2023
Figure 26. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2019-2024)
Figure 27. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application in 2023
Figure 28. Global Alpha- Antitrypsin Deficiency Treatment Sales Growth Rate by Application (2019-2024)
Figure 29. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region (2019-2024)
Figure 30. North America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 32. U.S. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Alpha- Antitrypsin Deficiency Treatment Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Alpha- Antitrypsin Deficiency Treatment Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 37. Germany Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023
Figure 44. China Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 50. South America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Country in 2023
Figure 51. Brazil Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Alpha- Antitrypsin Deficiency Treatment Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Alpha- Antitrypsin Deficiency Treatment Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Alpha- Antitrypsin Deficiency Treatment Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Type (2025-2030)
Figure 65. Global Alpha- Antitrypsin Deficiency Treatment Sales Forecast by Application (2025-2030)
Figure 66. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Application (2025-2030)
